Biobanking Market Size, Share, Trend, Key Manufacturer Analysis and Forecast to 2023

Market Highlights

Factors such as the increasing prevalence of chronic diseases and rising therapeutics demand are estimated to drive the market growth during the forecast period. Additionally, advancements in diagnostic and treatment technologies boost the market. However, low awareness and lack of healthcare services in the middle and low-income countries are estimated to restrain the market growth during the projected period.

Segmentation

The global biobanking market is segmented on the basis of products and services, sample type, storage type, application, end-user, and region. Considering products and services, the market is segmented into equipment, consumables, services, and software. Equipment is further sub-segmented into storage equipment, sample analysis equipment, sample processing equipment, sample transport equipment, and others. Consumables are further sub-segmented into storage consumables, analysis consumables, processing consumables, collection consumables, and others. Services are sub-segmented into storage services, processing services, transport services, and supply services. By sample type, the market is segmented into blood products, human tissues, cell lines, nucleic acids, biological fluids, and others. Based on storage type the market is segmented into manual storage and automated storage. On the basis of application, the market is segmented into regenerative medicine, life science research, and clinical research. By end-user, the market is segmented into hospitals, diagnostic laboratory, research centers, and others. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/5967

Regional Analysis

The Americas dominates the global biobanking market owing to the increasing prevalence of chronic diseases and presence of a well-developed healthcare sector within the region. Moreover, the increasing healthcare expenditure and presence of key players within the regional boundaries provide a favorable background for the market growth.

Europe is the second largest in the global biobanking market. Factors such as the increasing availability of funds for research and a huge patient population followed by a well-developed healthcare sector drive the market within the region.

Asia Pacific is estimated to be the fastest growing market for biobanking. This can be attributed to the presence of developing economies such as India and China. Moreover, the increasing healthcare expenditure and a rapidly developing healthcare sector boost the market growth within the region.

On the other hand, the Middle East and Africa has the least share in the global biobanking market due to low per capita healthcare expenditure and stringent government policies, especially within the Africa region. It is estimated that the Middle East holds a majority of the market within the Middle Eastern and African region. 

Key Players

Some of the key players in this market are Hamilton Company, Greiner Holding AG, Promega Corporation, Becton Dickinson and Company, Merck KGaA, VWR Corporation, Tecan Trading AG, Thermo Fisher Scientific Inc., Panasonic Healthcare Holdings Co., Ltd, Qiagen N.V., Brooks Automation, Inc., Chart Industries, Inc., and others.

Access Report @ https://www.marketresearchfuture.com/reports/biobanking-market-5967

Doxorubicin Market Developments, Trends, and Forecast By 2023

Market Highlights

Doxorubicin is a type of chemotherapy medicine called an anthracycline. It is used to reduce or diminish the growth of cancer cells by blocking an enzyme called topo isomerase. Factors that are propelling the growth of the doxorubicin market are surge in geriatric population, rising prevalence of different types of cancer, increasing awareness for cancer treatment. According to the International Federation of Pharmaceutical Manufacturers & Associations, global pharmaceutical industry has spent more than USD 149.8 billion on pharmaceutical Research and development activities.

The various side effects, cost containment policies by various governments, stringent regulatory environment for product approval, are likely to hinder market growth during the forecast period.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/7376

Regional Analysis

The American market is expected to dominate the global doxorubicin market during the forecast period due to the presence of major manufacturers, increase in number of cancer cases, awareness for the treatment of cancer, and favorable reimbursement and regulatory authorities. The European market is expected to be the second-largest due to growing pool of cancer patients and rising healthcare expenditure. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the increasing geriatric population in countries such as India and China, increasing awareness programs for the treatment of cancer, government initiatives and investment for the development of healthcare sector and increasing number manufacturers finding opportunities in developing countries. T0he market in the Middle East & Africa is likely to account for the smallest share of the global doxorubicin market.

Segmentation

The global doxorubicin market has been segmented on the basis of application, and distribution channel.

The application segment is divided into liver cancer, gastric cancer, breast cancer, bone sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.

The market, by distribution channel, has been segmented into hospital pharmacy, retail pharmacy and others.

Key Players

Some of the key players in the global Doxorubicin market are Doxorubicin market are Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Accord Healthcare, Novartis AG, Sandoz, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals, GLENMARK PHARMACEUTICALS LTD. and various others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/doxorubicin-market-7376

Gastric Bypass Market Estimated to Flourish by 2023

Market Highlights

Minimally invasive procedures are now being preferred by the healthcare provider and the patients. Gastric bypass is one of the bariatric surgical procedures used to treat obesity across the globe. Additionally, the progress of medical device industry in developed regions across the globe also influences the demand for surgical devices. Diabetes and obesity are the major risk factors for the cardiovascular disease, whose prevalence is found to be increasing from last few years.

The global gastric bypass market is expected to grow at a CAGR of 6.1 % during the forecast period 2017-2023.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/5321

Regional Analysis

The Americas dominate the global gastric bypass market owing to the technological advancement in the field of medical devices, a huge patient population with obesity and diabetes and increasing healthcare spending. As per the Obesity Society, in the U.S., in 2014, 28.1% people were obese. The obesity prevalence ranged from 30.3% for men and women aged 20-39 years to 39.5% and 35.4%, respectively, for men and women aged 40-59 years and ages 60 and over.    

Europe holds the second largest share of the global gastric bypass market as result of increasing focus of various government agencies on the treatment of chronic diseases. Additionally, the high prevalence of diabetes and increasing government support for research & development influences the market growth.  Moreover, rising awareness about gastrointestinal diseases among the people also accelerates the market growth. According to the World Health Organization (WHO), about 60 million European live with diabetes and the prevalence of diabetes is relatively high among people over 25 years. 

The Asia Pacific is expected to be a fastest growing market for gastric bypass owing to increasing demand for minimally invasive procedures and huge geriatric population. Japan holds the major share of the Asia Pacific market due to the availability of technologically advanced medical devices and huge healthcare spending. Moreover, increasing healthcare expenditure and the government’s initiatives for research & development projected to drive the market in China and India over the forecasted period.  

In the Middle East & Africa, the market exhibits steady owing to low technology penetration in developing regions, and focus on primary care services. The United Arab Emirates (UAE), Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.

Segmentation

The global gastric bypass market is segmented on the basis of type, indication, and end user. On the basis of type, it is segmented into endoscopic sleeve gastroplasty and intragastric balloon. Based on the indication, it is segmented into obesity, gastroesophageal reflux disease, heart disease, high blood pressure, type 2 diabetes, and others. On the basis of the end user, it is segmented into hospitals & clinics, surgical centers, and others.

Key Players

Some of key the players in the market are Medtronic (U.S.), Intuitive Surgical Inc. (U.S.), TransEnterix Inc.  (U.S.), ALLERGAN (Republic of Ireland), USGI Medical Inc. (U.S.), Cousin Biotech (France), GI Dynamics Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Mediflex Surgical Product (U.S.), and others.

Browse Full Report @ https://www.marketresearchfuture.com/reports/gastric-bypass-market-5321

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Ulcerative Colitis Market to Record Sturdy Growth by 2022

Market Highlights

The global Ulcerative colitis market has been evaluated as growing market and expected that the market will reach high growth figures in the coming future. Ulcerative colitis is a type of inflammatory bowel disease (IBD) that usually affects the lower section of body such as sigmoid colon and the rectum. Belly pain or cramps, diarrhea and bleeding from the rectum are some of the common symptoms of the diseases. According to CDC, the worldwide incidence of ulcerative colitis is between 0.5 to 24.5 cases per 100,000 persons per year. The reappearance of the disease’s symptoms is also high. According to Colitis Foundation of America, about 30% of the people on remission are expected to suffer from the disease flare-up in the future following the treatment and remission.

Major factors leading to the growth of the market includes increasing prevalence of ulcerative colitis, higher preference for symptomatic therapeutic, better treatment of inflammatory bowel diseases, arrival of enhanced drugs and healthier investments in R&D programs. Increasing patient pool with unmet needs, new drugs entering the market, increasing global incidence & prevalence rate, and increasing investments towards research in small molecules are some of the other factors leading the market growth. Blockbuster drugs losing patent protection and growing the propensity for generic drugs are turning out to be restraints for the market. The lack of curative therapy and personalized therapy and medication are big opportunities for the market.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/2354

North America is expected to account for the largest share of the global Ulcerative colitis Market in 2016, followed by Europe, the region will continue to lead the pack during the forecast period. In Asia-Pacific, China leads the market. Economic development and improvement of healthcare facilities are propelling the growth of the market. The entry of Simponi and Entyvio is likely to petrol the growth of the market. However, Humira which lost its patent in 2016 and Remicade, which will lose its patent in 2018 and will not have a positive impact on the market.

Key Players:

Key players profiled in the report are Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, and Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., Ferring B.V., Janssen Biotech, and Merck

Segmentation:

Global Ulcerative Colitis Market is segmented on the basis of types and medication. Based on types, the market is segmented as ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Ulcerative proctitis is expected to command the largest market share during the forecast period. Further on the basis of medication the market is classified into 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics. Biologics are expected to command the largest market. Steroids drugs are expected to grow at the highest CAGR during the forecast period.

Access Report Details @ https://www.marketresearchfuture.com/reports/ulcerative-colitis-market-2354

Surgical Stapler Market to Register Steady Growth By 2023

Market Highlights

Major factors driving the growth of this market are the increasing number of surgical procedures, technological advancements, and increasing preference for surgical staplers over sutures. Many companies are increasing their focus on the development of technologically advanced surgical staplers in order to strengthen their product portfolio in the surgical stapler market. However, the growing geriatric population in need of surgical procedures and better insurance coverage policies will increase the market share of the global surgical stapler market.

On the other hand, the high cost of surgical staplers and the availability of alternative wound care techniques may hinder the growth of the market.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/6382

Regional Analysis

North America will dominate the surgical stapler market during the forecast period. Technological advancements, growing geriatric population, and rising number of surgical procedures are likely to drive the surgical stapler market during the forecast period. North America and Europe are expected to hold a major share of around 70% of the surgical stapler market during the forecast period. The European market is expected to be the second-largest surgical stapler market. The market growth in this region can be attributed to the increasing awareness and adoption of advanced surgical technology. Asia-Pacific is expected to be the fastest-growing surgical stapler market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving strong competition to the global surgical stapler market by producing cost-effective treatments that are high in demand in local as well as global markets. The market in the Middle East and Africa is expected to account for the smallest share in the global surgical stapler market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Segmentation

The global surgical stapler market is segmented into types, product, application, and end-users. Based on types the surgical stapler market is segmented into disposable surgical staplers and reusable surgical staplers. On the basis of product, the market is segmented into manual surgical staplers and powered surgical staplers. Based on application, the surgical stapler market is segmented into abdominal and pelvic surgery, general surgery, cardiac and thoracic surgery, orthopedic surgery, and other surgical applications. Based on end-user the market is segmented into hospitals, ambulatory surgical centers (ASCs), and clinics.

Key Players

Some of the key players in the global surgical stapler market are  Ethicon. US, LLC., Cardica Inc, Smith and Nephew Plc, CONMED Corporation, Purple Surgical Inc., Welfare Medical Ltd, Reach Surgical, Grena Ltd, B.Braun Melsungen AG, Frankenman International Limited, Zimmer Biomet, Stryker, Meril Life Sciences Pvt. Ltd., Touchstone International Medical Science Co. Ltd, Medtronic.

Access Report @ https://www.marketresearchfuture.com/reports/surgical-stapler-market-6382

Cell Isolation Market to Significant Growth Foreseen by 2023

Cell Isolation is a sophisticated process which physicians employ in order to find out how cells are affected by different diseases and how they respond to different drugs. Market Research Future (MRFR) has published and released a research report about the global cell isolation market that predicts massive proliferation of this market with 17.8% CAGR during the forecast period between 2018 and 2023. In terms of cash, the market is expected to be worth the USD 10,500 mn.

The key market growth drivers for cell isolation include advances in cell analysis techniques, increased government funding for cell-based research, increasing use of cell isolation process in various healthcare technologies, and rising cancer prevalence.

The global cell isolation market has been segmented on the basis of application, cell type, end-user, product, technique, and lastly region. Based on application, this market has been segmented into biomolecule isolation, cancer research, stem cell research, in vitro diagnostics, therapeutics, and tissue regeneration. By cell type, the market has been segmented into animal cell type and human cell type. Based on the end user, the market biotechnology & biopharmaceutical companies, cell banks, diagnostic laboratories, research laboratories & institutes, and hospitals.

As per product-based segmentation, the market has been segmented into consumables and instruments. Consumables have been sub-segmented into beads, disposables, reagents, kits, media, and sera. Instruments have been sub-segmented into centrifuges, filtration systems, flow cytometers, and magnetic-activated cell separator systems. Technique segments the market into centrifugation-based cell isolation, surface marker-based cell isolation, and filtration-based cell isolation.

The regional segmentation of the global cell isolation market segments the market into continent-based regional markets known as The Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa (MEA). The Americas has the potential to be the biggest market because North America has the most advanced medical facilities available and rapid technological advancement. The biggest country-specific markets in this region are the United States of America (USA) and Canada. USA is the strongest economy in North America and many key players in this market are based in the USA. South America is a significant market, but technologically, it is not as advanced as North America. The strongest economies that have the potential to emerge as the strong markets in South America are Argentina and Brazil.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/6193

After the Americas, it is Europe that has maximum technological advancement and advanced medical facilities. Europe also has a large population. Due to the reasons same as the Americas, Western Europe has a stronger economy and hence, is a bigger market than Eastern Europe. The most important country-specific markets in Western Europe are France, Germany, Italy, Spain, and the United Kingdom (UK) followed by the rest of Western Europe and the whole of Eastern Europe.

In the Asia Pacific, the market is steady as advanced medical facilities are not available in all countries. The rising economies have good medical facilities and China, India and Japan are the most significant country-specific markets here. Other important markets in this region are Australia and South Korea, followed by the rest of the Asia Pacific region.

In the MEA region, the market is small and limited. Reasons for the limited market growth in this region are lack of awareness, lack of education, lack of technological development, political instability and healthcare not being considered a priority by the government.

Key Players

The key players in the global cell isolation market include Becton Dickinson and Company (USA), Bio-Rad Laboratories Inc. (USA), Beckman Coulter (USA), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (USA), Merck KGaA (Germany), Miltenyi Biotec (Germany), Thermo Fisher Scientific Inc. (USA), Stemcell Technologies (Canada), and Terumo Corporation (Japan).

Latest Industry Technology

• Celsee Inc. has launched the Genesis system, which has been designed to overcome the limitations of other tools for single-cell analysis. 25 OCT 2018
• CCM Duopharma Biotech Bhd has acquired a 5.8% stake in SCM Lifescience Co Ltd. Based in South Korea , SCM Lifescience Co Ltd. is research-based biopharmaceutical company that is developing cell therapeutics for autoimmune diseases.

Access Report @ https://www.marketresearchfuture.com/reports/cell-isolation-market-6193

Sexual Wellness Market Expected to Increase at a CAGR 9.2% through 2023

Market Highlights

The global sexual wellness anticipated to have held a market value of USD 21.26 billion in the year 2017 and is expected to grow at a CAGR of 9.2% during the forecast period. Sexual health is experience of physical, psychological and social cultural related to sexuality. The products such as, sex toys, condom & contraceptives, sexual enhancement supplements, lubricants, ointments view as a sexual wellness product that provides enjoyment in sexual experience and security.

Increasing global prevalence of Sexually Transmitted Diseases (STDs), increase in awareness regarding sexual health items, and development of e-commerce business are expected to drive the growth of market. According to the Centers for Disease Control and Prevention (CDC), in 2017 around 1,708,569 were suffer with Chlamydia trachomatis infection in US. Similarly, in 2017, around 555,608 were suffer with gonorrhea and 30,644 were suffer with Syphilis in US. Moreover, According to World Health Organization (WHO), every year estimated around 357 million new people suffer with sexually transmitted infections (STIs). Furthermore, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2017 estimated that 5.2 million suffer with HIV in Asia-Pacific. On other hand, side effects due to toxic ingredients in products and product recalls can restrain the market growth over the assessment period.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/7328

Regional Analysis

Geographically, the Americas is expected to dominate the global sexual wellness market owing to the presence of well-established players, increasing prevalence of Sexually Transmitted Diseases (STDs), increase in awareness regarding sexual health items, and developed e-commerce business. Europe is expected to hold the second largest position in the global sexual wellness market. Asia-Pacific is expected to be the fastest growing market owing to the increasing awareness about sexual wellness products and supportive sex education programs. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global sexual wellness market.

Segmentation

The global sexual wellness market has been segmented into product and distribution channels.

Based on product, sexual wellness market is segmented into sex toys, condom & contraceptives, sexual enhancement supplements, lubricants, ointments, and others. The sex toys segment is expected to account for the largest share segment of the market in 2017.

Based on distribution channels, sexual wellness market is segmented into retail and online platforms. The retail segment is expected to account for the largest share segment of the market in 2017. Retail segment further sub segmented into drug stores, specialty stores, and others.

Key Players

Some of the prominent players in the global sexual wellness market are LELO (Sweden), Doc Johnson (US), Church & Dwight Co., Inc. (US), Ansell Ltd. (Australia), Reckitt Benckiser Group plc (UK), LifeStyles Healthcare (Australia), Karex Berhad (Malaysia), Veru Inc. (US), Mankind Pharma (India), and BioFilm IP LLC (US).

Browse Complete Report @ https://www.marketresearchfuture.com/reports/sexual-wellness-market-7328

Vascular stents market to Witness Significant Incremental Opportunity By 2023

Global Vascular Stents Market - Overview

Vascular stents are tiny tube like medical devices which are places into blood vessels or arteries to open the blockage in the vessels. Vascular stent is the valuable tool for the treatment of the different coronary diseases. Vascular stents are used to widen the narrow vessels so as to minimize the chances of heart attack and chest pain. This stents are prepared from variety of material. According to the WHO, approximately 18 million people died from cardiovascular diseases in 2014. Increasing number of people suffering from cardiovascular diseases is responsible for the driving the market. Additionally, globally 39% of adults aged 18 years and over were overweight whereas 13% were obese. Technological advances and increasing obese population is also contributed in the growth of the market. Other advantages like low risk of infection and short recovery time will also drive the market. However availability of alternative therapy and high cost of ventricular stents may restrain the growth of the market.

Global Vascular Stents Market   - Competitive Analysis

Boston Scientific Corporation (US), Abbott Laboratories (US), Medtronic, Plc (UK), Cook Medical (US), Biotronik se & co. kg (Germany), B. Braun Melsungen AG (Germany), Cordis (US), Lombard Medical Technologies (UK), Translumina GmbH (Germany), MicroPort Scientific Corporation (China), Terumo Corporation (Japan), Vascular Concepts (India), W.L. Gore & Associates (US), Meril Life Sciences Pvt. Ltd. (India) are some of the prominent players at the forefront of competition in the Global Vascular Stents Market and are profiled in MRFR Analysis. 

Many companies are focusing on research and development activity to improve the vascular stent products.  Major companies are focusing on the development of biodegradable stents to overcome the disadvantages of other available stents. Some major has adopted strategies of acquisitions and strategic alliances for the growth of the market.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/1408

Abbott Laboratories is one of the leading healthcare company headquartered in US. In June 2016, FDA has approved the Absorb bioresorbable Stent for heart. This stents is completely dissolve in the body and used in the treatment of heart complications. Company’s Esprit bioresorbable vascular scaffold is under clinical trials.

December, 2016 - Lombard Medical and MicroPort Scientific Corporation announced strategic partnership and investment agreement. This partnership allowed Lombard Medical to accelerate commercialization in global market with its two key products i.e Aorfix and Altura AAA. Aorfix, the only stent graft to hold global approvals to treat abdominal aortic aneurysms (AAA) with aortic neck angles up to 900, and Altura, a highly innovative stent graft that offers a simple and predictable treatment option for standard abdominal aortic aneurysms anatomy.

Boston Scientific Corporation is a global manufacturer and developer of medical devices headquartered in US. PROMUS Element Plus Stent, REBEL Stent System, SYNERGY Stent are some of the major products of the company. In 2014, company has launched Promus PREMIER Everolimus-eluting Platinum Chromium Coronary Stent System in Asia Pacific region. In 2015, worldwide sales of the company’s drug-eluting coronary stents were $1.074 billion as compared to $1.151 billion during 2014.

Medtronic is a medical device manufacturer headquartered in UK. It is the world's largest standalone medical technology development company. In 2015 company has develop Stent Graft System System for Endovascular Repair of Thoracoabdominal Aortic Aneurysms. Earlier company’s Resolute Drug-Eluting Stent has shown a very good performance in Diabetic Patients with Heart Disease. Medtronic market was increased by 7% in 2016 compared to 2015.

Cook Medical is an US headquartered company involved in the manufacturing of the medical devices. Approach, Bird's Nest, Advance are some of the major product of the company.

Global Vascular Stents Market   - Regional Analysis

Geographically, the global vascular stents market is segmented into four regions. Of which North America commands market for vascular stents due to increasing obese population in North America is the major factor for the growth of the market. Beside this increasing people suffering from various cardiovascular diseases and lack of exercise also contributed in the growth of the market. Europe accounts second largest vascular stents market. While Asia Pacific is the fastest growing market due to rapid development in technology and a huge patient suffering from different vascular diseases. However, The Middle East and Africa has the lowest market for medical robotics because of limited development in medical field.

Browse Full Report @ https://www.marketresearchfuture.com/reports/vascular-stents-market-1408

Sex Cord Gonadal Stromal Tumor Market to Witness an Outstanding Growth by 2023

Market Highlights

Owing to the increasing cases of ovarian and testicular cancer, technological advancements, increasing healthcare expenditure, growing awareness about sex cord-gonadal stromal tumor, unmet medical needs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement, the sex cord-gonadal stromal tumor market has evolved significantly.

However, huge capital investments with low-profit margins, strict FDA regulations, and poor healthcare system in low and middle-income countries are likely to hamper the growth of the sex cord-gonadal stromal tumor market over the forecast period.

It is estimated that the sex cord-gonadal stromal tumor market is expected to grow at a CAGR of 6.5% during the forecast period of 2017–2023.

Regional Analysis

The Americas dominates the sex cord-gonadal stromal tumor market owing to the increasing prevalence of ovarian cancer in this region and high healthcare expenditure. According to the American Cancer Society, around 22,240 women are likely to be diagnosed with ovarian cancer, and 14,070 women are likely to die from ovarian cancer, in 2018.

Europe holds the second position in the sex cord-gonadal stromal tumor market. The financial support provided by the government towards R&D and technological advancements are expected to drive the European sex cord-gonadal stromal tumor market. The increasing healthcare expenditure is also boosting the European sex cord-gonadal stromal tumor market.

According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014, i.e., EUR 321 billion which is further followed by France with EUR 237 billion and United Kingdom with EUR 223 billion. In 2016, the R&D expenditure in the pharmaceutical industry was EUR 35000 million, suggested by the European Federation of Pharmaceutical Industries and Association.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/5912

Asia Pacific is the fastest growing sex cord-gonadal stromal tumor market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015–2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014–2015.

The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.

Segmentation

The global sex cord-gonadal stromal tumor market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of tumor type, the sex cord-gonadal stromal tumor market is classified as granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, Sertoli Leydig cell tumor, gynandroblastoma, and Sex Cord Tumor with Annular Tubules (SCTAT). The granulosa cell tumor is further classified as functioning tumors and non-functioning tumors.

On the basis of diagnosis, the sex cord-gonadal stromal tumor market is classified as microscopy immunohistochemistry, tumor marker, ultrasound, Magnetic Resonance Imaging (MRI), and others. The tumor marker segment is further classified as inhibin-alpha, calretinin, Melan-A, and others.

On the basis of treatment, the sex cord-gonadal stromal tumor market is classified as chemotherapy, radiotherapy, surgery, and others. The surgery segment is further classified as salpingo-oophorectomy, abdominal hysterectomy, Retroperitoneal Lymph Node Dissection (RPLND), and radical inguinal orchiectomy. The sub-segment of salpingo-oophorectomy includes unilateral salpingo-oophorectomy and bilateral salpingo-oophorectomy.

On the basis of end-user, the sex cord-gonadal stromal tumor market is segmented into hospitals and clinics, cancer research centers, research and academic institutes, and others.

Key Players

Some of the key players in the global sex cord–gonadal stromal tumor market are Abbott, Abcam plc, Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company (BD), Bio SB Inc., BioCurex, BioModa, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cell Signaling Technology, Inc., Clarient, Inc., CooperSurgical Inc., Correlogic Systems, Inc., Danaher Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Gen-Probe, Inc., Hologic, Inc., Johnson & Johnson Services, Inc., Karl Storz GmbH & Co. Kg, LiNA Medical USA, Merck Millipore, PerkinElmer, Inc., Qiagen, Radient Pharmaceuticals, Thermo Fisher Scientific Inc., Veridex LLC, and others.

Access Report Details @ https://www.marketresearchfuture.com/reports/sex-cord-gonadal-stromal-tumor-market-5912

Aortic Coarctation Market Witness Rapid Increase in Consumption By 2022

Global Aortic Coarctation Market Information, by treatment (Balloon angioplasty, Patch aortoplasty, Subclavian flap aortoplasty and others), by end user (Hospital, Clinic, Cardiac Institutes and others) - Forecast to 2022

Market Scenario:

Coarctation of the aorta (CoA) is a type of defect which causes narrowing of aorta and accounts for nearly 5-8% of all congenital heart defects. It may occur as an isolated defect or may occur in association with various other lesions such as commonly bicuspid aortic valve and ventricular septal defect (VSD). It may be found more frequently in infants with symptoms prior to age one year.

The global market for Aortic Coarctation is expected to reach USD XX million by the end of the forecasted period and is expected to grow at a CAGR of ~3.8%.

Key Players for Global Aortic Coarctation Market:

Some of the key players in this market are: Creganna (Ireland), Medtronic (Ireland), Freudenberg Medical, LLC (Germany), Clada Medical Devices (Ireland), B. Braun Melsungen AG (Germany), Braile Biomedica (Brazil) and others.

Segments:

Global Aortic Coarctation market has been segmented on the basis of type which comprises of Balloon Angioplasty, Patch Aortoplasty, Subclavian Flap Aortoplasty and others. On the basis of end user; market is segmented into Hospital, Clinic, Cardiac Institute and others.

Regional Analysis of Global Aortic Coarctation Market:

Globally North America is the largest market for Aortic Coarctation. The North American market for Aortic Coarctation is expected to reach at USD XX Million by the end of the forecasted period.

Europe is the second-largest market for Aortic Coarctation which is expected to grow at a CAGR of XX%. Asia pacific region is expected to be fastest growing region in Aortic Coarctation market.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/1854

Study Objectives Global Aortic Coarctation Market:

To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the Global Aortic Coarctation Market

To provide insights about factors affecting the market growth

To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

To provide country level analysis of the market with respect to the current market size and future prospective

To provide country level analysis of the market for segments by type, by end user and other sub segments.

To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Intended Audience

Medical device manufacturers

Medical device suppliers

Government Research Laboratory

Research and Development (R&D) Companies

Market Research and Consulting Service Providers

Medical Research Laboratories

Key Finding

The global Aortic Coarctation market and is expected to reach USDXX million by 2022.

Regionally, North America holds the largest market share for global Aortic Coarctation market and is expected to reach USDXX million by 2022.

Asia Pacific market is expected to be the fastest growing market, and expected to reach at USD XX million by 2022.

On the basis of type, Balloon angioplasty segment holds largest market share.

Get full report & TOC @: https://www.marketresearchfuture.com/reports/aortic-coarctation-market-1854

RSV Diagnostics Market Scenario Highlighting Major Drivers & Trends, 2023, says MRFR

Market Highlights

Respiratory Syncytial Virus (RSV) is a virus that can cause serious respiratory infections such as pneumonia and bronchitis. The increasing incidence rate of respiratory infections, growing demand for in-vitro diagnostics, and growing neonatal population are major factors propelling the growth of the market. For instance, according to the Centres for Disease Control and Prevention, in the United States, RSV on an average lead to 57,527 hospitalizations among children below five years of age. On the other hand, some factor such as lack of availability of specific treatment options for RSV infections and the high number of other pathogens that cause similar symptoms of respiratory illness may hamper the growth of the market during the assessment period.

Regional Analysis

The Americas is likely to dominate the global RSV diagnostics market during the forecast period. The market growth is attributed to increasing incidences of RSV infections, increasing government funding's, and increasing infant population. Additionally, growing demand for molecular diagnostics and chromatographic immunoassays in this region owing to the high accuracy, sensitivity, and specificity these devices provide. For instance, as per the data stated by the Centres for Disease Control and Prevention, in the United States, RSV leads to an estimated 2.1 million outpatient visits among children below five years of age every year. Europe is anticipated to be the second largest market in the global RSV diagnostics market. The European market is expected to grow during the forecast period owing to the growing occurrence of RSV infections and growing government funding for respiratory diseases. Asia Pacific is expected to be the fastest growing market owing to the high population base, increasing prevalence of respiratory diseases such as pneumonia and bronchitis, and growing demand for automated healthcare testing for the accurate diagnosis of diseases. Furthermore, the Middle East and Africa are expected to show the least growth in the global RSV diagnostics market. The market growth in these regions is attributed to the constantly improving healthcare infrastructure, economic development, and rising patient awareness levels.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/6217

Segmentation

The global RSV diagnostics market is segmented on the basis of the product, method, and end-user. On the basis of the product, the market is classified into kits and assays, instruments, and other products. The global RSV diagnostics market on the basis of the method is segmented into molecular diagnostics, rapid antigen detection test, gel microdroplets, flow cytometry, and others. The rapid antigen detection tests are further classified into enzyme-linked immunosorbent assays, immunofluorescence assays, and other rapid antigen detection tests. Further, the other rapid antigen detection tests are classified into chromatographic immunoassays and optical immunoassays. Furthermore, on the basis of end-user, the market is segmented into hospitals and clinics, clinical laboratories, home care, and others.

Global RSV Diagnostics Key Players

Some of the key players in the global RSV diagnostics market are Quest Diagnostics, Biomerieux, Becton, Dickinson, and Company (BD), Abbott, F. Hoffman-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Biocartis, Luminex, Hologic, Fast Track Diagnostics, Bio-Rad Laboratories Inc., Alere, Inc., Quidel Corporation, and others.

Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

....Continued

Get full report & TOC @: https://www.marketresearchfuture.com/reports/rsv-diagnostics-market-6217

Healthcare BPO Market Predicted to Witness Surge in The Near Future

Market Research Future Published a Cooked Research Report on Healthcare BPO Market Research Report.

Market Research Future (MRFR)’s latest study reveals that the global healthcare BPO market is projected to thrive exponentially striking a CAGR of 12.3% during the forecast period 2017 to 2023. The market is projected to reach a valuation of USD 449,623.8 Mn by 2023-end up from USD 199,533.8 Mn in 2017. The accelerating revenue from the healthcare sector coupled with the increasing demand from fast-developing economies is anticipated to catalyze the expansion of the healthcare BPO market.

Loss of revenue due to poor billing practices and maintenance are the key areas of focus in the healthcare sector. According to a published research report, a loss of USD 125 Bn is incurred every year due to inefficient billing practices. It has intensified the demand for the adoption of BPO in the healthcare sector globally. The trend is poised to perpetuate through the assessment period.

The enormous costs associated with the healthcare facilities remain a challenge to the industry leaders. Thus, a shift towards outsourcing has been witnessed for bringing health care costs down by 30% to 60%, and it is likely to continue through the review period. Furthermore, outsourcing ensures operational efficiency by professionals which is expected to passively fuel demand in the market. Nevertheless, increasing complaints regarding poor BPO services are estimated to slow down the rate of growth by 0.5% to 1% in the foreseeable future.

Request Free Sample @: https://www.marketresearchfuture.com/sample_request/1335

Global Market for Healthcare BPO-Segmental Analysis:

MRFR’s report offers a detailed segmental analysis of the market on the basis of services. By services, the global healthcare BPO market has been segmented into pharmaceutical services, payer services, and provider services. The pharmaceutical services segment is sub-segmented into research and development, manufacturing, and non-clinical Services. The payer services segment has been sub-segmented into claim management, member management, provider management, care management, and product development & business acquisition. The provider services segment is further sub-segmented into medical billing, medical coding, medical transcription, and finance & accounts.

The pharmaceutical services segment held the maximum share of the market in 2016 and is estimated to register a CAGR of 12.4% during the forecast period. The segment is poised to grow from USD 125,849.8 Mn in 2016 to USD 329,000.3 Mn by 2023.

Regional Outlook:

By region, the healthcare BPO market has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas hold a significant share of the global healthcare BPO market. It is likely to exhibit substantial growth over the next couple of years. The factors such as rising healthcare expenditure, technological advancements, increasing health awareness about healthcare facilities, etc. have augured well for the market players. Additionally, the presence of key players and its strategies for gaining traction in the market are poised to have a positive influence on the expansion of the regional market. The region is well equipped for the adoption of the latest technologies, which when coupled with government support is projected to lead the growth of the healthcare BPO market.

Europe is expected to remain a highly lucrative market through the projection period. The growth is mostly attributable to the high expenditure in the healthcare sector. According to a report published by OECD, in 2014, the healthcare expenditure of Germany accounted for EUR 321 Bn, trailed by France whose healthcare expenditure was valued at EUR 237 Bn. The market in Europe resonates strong growth opportunities due to the firm support provided by the governments and the availability of funds for the development of the facilities. The regional market in Europe is further sub-segmented into Western and Eastern Europe. Western Europe is set to exhibit a relatively higher CAGR during the assessment period.

Access Report @ https://www.marketresearchfuture.com/reports/healthcare-bpo-market-1335

Asia Pacific is projected to thrive at a relatively higher CAGR. The factors responsible for catapulting the market on an upward trajectory are rapidly evolving healthcare sector, opportunities present for the development of this market, developing healthcare industries & organizations, and improving technology. According to the World Health Organization (WHO), the per capita health care expenditures in Australia and Japan were USD 6,110 and USD 3,966 in 2013. Additionally, healthcare spending in China is expected to grow at a rate of 8.8% during 2015-2018. The trend is likely to continue and benefit the proliferation of the healthcare BPO market in Asia Pacific.

Global Market for Healthcare BPO-Competitive Dashboard:

Some of the key players profiled by MRFR are Sykes, Accenture, HCL, IBM, Cognizant, and INFOSYS among others.

Mucormycosis Market to Perceive Substantial Growth During 2017 – 2023

Market Scenario:

Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.  

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/5440

These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.

The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.

The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.

Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the global mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.

The global market for mucormycosis is expected to grow at a CAGR of approximately 7.3% during the forecast period, 2017-2023.

Key Players:

The Global Mucormycosis Market key players are Abbott Laboratories (U.S.), Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others

Segmentation:

The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.

On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others

On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.

On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Browse Full Reports @ https://www.marketresearchfuture.com/reports/mucormycosis-market-5440

Regional Analysis:                     

The Global Mucormycosis Market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominate the global mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.

Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.

Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.